Genome-Wide Methylation Landscape Identifies Drivers of Early Carcinogenesis
Aberrant DNA methylation is an early hallmark of malignant transformation. We profiled the genome-wide methylation landscape of 480 pre-malignant and tumour spe…
Current Issue
This is a peer-reviewed, open-access journal dedicated to the genomic and epigenomic drivers of cancer. We publish original research, methodological advances and critical reviews spanning tumour evolution, epigenetic regulation, liquid biopsy and precision oncology.
All articles are freely available on publication under a Creative Commons licence, with no article processing charges to authors.
Aberrant DNA methylation is an early hallmark of malignant transformation. We profiled the genome-wide methylation landscape of 480 pre-malignant and tumour spe…
A subpopulation of drug-tolerant persister cells underlies relapse after targeted therapy. We characterised persister states in lung adenocarcinoma using paired…
Intratumoural heterogeneity shapes treatment response. We applied single-cell DNA and RNA sequencing to 36 colorectal tumours spanning disease stages, reconstru…
Circulating tumour DNA enables non-invasive cancer detection. We developed a next-generation sequencing assay targeting methylation and mutation signals simulta…
The tumour suppressor p53 safeguards genome integrity. We modelled p53 loss in organoids and tracked the emergence of structural variation over 40 passages. p53…
The tumour microenvironment is epigenetically remodelled during progression. We mapped methylation changes in stromal and immune compartments of breast tumours …
Synthetic lethality exploits tumour-specific dependencies. We performed genome-wide CRISPR screens in BRCA-mutant cancer lines to map DNA-repair vulnerabilities…
Mismatch-repair deficiency predicts immunotherapy benefit, but finer stratification is needed. We analysed DNA-repair signatures across 2,400 treated patients, …
Evasion of apoptosis is a core hallmark of cancer and a driver of therapy resistance. We dissected apoptotic priming in matched pre- and post-treatment biopsies…
Polygenic background modifies penetrance in hereditary cancer. We built a polygenic risk model in 18,000 carriers of high-penetrance variants across five syndro…
Telomere attrition precipitates a state of chromosomal instability that fuels tumour heterogeneity. We characterised telomere dynamics across 312 aggressive car…
KRAS-mutant cancers remain difficult to treat. We performed genome-wide CRISPR knockout screens across 28 KRAS-mutant tumour models to map synthetic-lethal inte…
Nominations for the 2026 Best Paper Award are open until 30 September. Any research article published in the journal during 2026 i…
More →We invite submissions for a themed collection on single-cell approaches to tumour evolution. Contributions addressing lineage trac…
More →Following changes to our editorial workflow, median time from submission to first decision has fallen to 18 days, down from 34 day…
More →The journal now accepts Registered Reports, in which study protocols are peer reviewed before data collection begins. Accepted pro…
More →A special issue on cancer epigenetics will be guest edited by Dr Ingrid Moreau. Topics include DNA methylation biomarkers, chromat…
More →Our forthcoming special issue focuses on liquid biopsy technologies for early cancer detection, covering assay development, clinic…
More →The journal has been accepted for indexing in Scopus and PubMed Central. All content published from volume 1 onwards will be retro…
More →From 1 August 2026, all articles reporting primary genomic data must deposit raw sequence data in a recognised public repository a…
More →We are expanding our reviewer pool in cancer genomics, computational biology and clinical oncology. Reviewers receive formal recog…
More →We welcome twelve new members to the editorial board for 2026, bringing expertise in single-cell genomics, epigenetics, immuno-onc…
More →